584 related articles for article (PubMed ID: 25480499)
1. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
[TBL] [Abstract][Full Text] [Related]
3. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
[TBL] [Abstract][Full Text] [Related]
4. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP
Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241
[TBL] [Abstract][Full Text] [Related]
5. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
6. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
7. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
Petrov JC; Wada M; Pinz KG; Yan LE; Chen KH; Shuai X; Liu H; Chen X; Leung LH; Salman H; Hagag N; Liu F; Jiang X; Ma Y
Leukemia; 2018 Jun; 32(6):1317-1326. PubMed ID: 29515236
[TBL] [Abstract][Full Text] [Related]
8. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Kim MY; Yu KR; Kenderian SS; Ruella M; Chen S; Shin TH; Aljanahi AA; Schreeder D; Klichinsky M; Shestova O; Kozlowski MS; Cummins KD; Shan X; Shestov M; Bagg A; Morrissette JJD; Sekhri P; Lazzarotto CR; Calvo KR; Kuhns DB; Donahue RE; Behbehani GK; Tsai SQ; Dunbar CE; Gill S
Cell; 2018 May; 173(6):1439-1453.e19. PubMed ID: 29856956
[TBL] [Abstract][Full Text] [Related]
9. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy.
Pizzitola I; Agostoni V; Cribioli E; Pule M; Rousseau R; Finney H; Lawson A; Biondi A; Biagi E; Marin V
J Immunother; 2011; 34(6):469-79. PubMed ID: 21654519
[TBL] [Abstract][Full Text] [Related]
10. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.
Minagawa K; Al-Obaidi M; Di Stasi A
Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529
[TBL] [Abstract][Full Text] [Related]
11. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.
Marin V; Pizzitola I; Agostoni V; Attianese GM; Finney H; Lawson A; Pule M; Rousseau R; Biondi A; Biagi E
Haematologica; 2010 Dec; 95(12):2144-52. PubMed ID: 20713459
[TBL] [Abstract][Full Text] [Related]
13. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
14. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.
Wang QS; Wang Y; Lv HY; Han QW; Fan H; Guo B; Wang LL; Han WD
Mol Ther; 2015 Jan; 23(1):184-91. PubMed ID: 25174587
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
[TBL] [Abstract][Full Text] [Related]
16. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
18. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia
Rennert PD; Dufort FJ; Su L; Sanford T; Birt A; Wu L; Lobb RR; Ambrose C
Mol Cancer Ther; 2021 Oct; 20(10):2071-2081. PubMed ID: 34253594
[TBL] [Abstract][Full Text] [Related]
20. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]